{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:54:38Z","timestamp":1785034478768,"version":"3.55.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.clinthera.2006.10.018","type":"journal-article","created":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T07:11:17Z","timestamp":1165389077000},"page":"1485-1508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Jacques-Pierre","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Delavault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.10.018_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib2","series-title":"Prostate Cancer Treatment Guidelines for Patients-Version V","author":"National Comprehensive Cancer Network in partnership with the American Cancer Society","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.018_bib3","series-title":"AstraZeneca Annual Report and Form 20-F Information 2004","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.018_bib4","series-title":"Commercial availability of QLT's Eligard\u00ae 6-month formulation brings new treatment option for advanced prostate cancer","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.018_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophinreleasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib6","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1210\/jc.2001-020243","article-title":"Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)","volume":"87","author":"Carel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib7","first-page":"285","article-title":"Primary gonadotropin-releasing hormone agonist therapy for suspected endometriosis: A nonsurgical approach to the diagnosis and treatment of chronic pelvic pain","volume":"3","author":"Barbieri","year":"1997","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2006.10.018_bib8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1210\/jcem.83.4.4696","article-title":"Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate)","volume":"83","author":"Mizutani","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib9","series-title":"Recent Progress on GnRH and Gonadal Peptides: Proceedings of the International Symposium","first-page":"261","article-title":"Use of GnRH analogs in in vitro fertilization (IVF)","author":"Frydman","year":"1990"},{"key":"10.1016\/j.clinthera.2006.10.018_bib10","first-page":"298","article-title":"Neural Control of the Pituitary Gland","author":"Harris","year":"1955"},{"key":"10.1016\/j.clinthera.2006.10.018_bib11","series-title":"Nobel Lectures in Physiology or Medicine 1971\u20131980","article-title":"Aspects of hypothalamic regulation of the pituitary gland with major emphasis on its implications for the control of reproductive processes. 1977","author":"Schally","year":"1992"},{"key":"10.1016\/j.clinthera.2006.10.018_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/joe.1.05883","article-title":"Hypothalamic hormones a.k.a. hypothalamic releasing factors","volume":"184","author":"Guillemin","year":"2005","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib13","first-page":"1870","article-title":"Molecular structure of the hypothalamic hypophysiotropic TRF factor of ovine origin: Mass spectrometry demonstration of the PCA-His_pro_NG2 sequence [in French]","volume":"269","author":"Burgus","year":"1969","journal-title":"C R Acad Sci Hebd Seances Acad Sci D"},{"key":"10.1016\/j.clinthera.2006.10.018_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1021\/bi00807a008","article-title":"Structure of porcine thyrotropin releasing hormone","volume":"9","author":"Nair","year":"1970","journal-title":"Biochemistry"},{"key":"10.1016\/j.clinthera.2006.10.018_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.173.4001.1036","article-title":"Gonadotropinreleasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones","volume":"173","author":"Schally","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2006.10.018_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-291X(71)90766-2","article-title":"Isolation and properties of the FSH and LH-releasing hormone","volume":"43","author":"Schally","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2006.10.018_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0006-291X(71)90623-1","article-title":"Structure of the porcine LH- and FSHreleasing hormone II. Confirmation of the proposed structure by conventional sequential analyses","volume":"44","author":"Baba","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2006.10.018_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0015-0282(16)38580-6","article-title":"Hypothalamic follicle-stimulating (FSH) and luteinizing hormone (LH)-regulating hormone: Structure, physiology, and clinical studies","volume":"22","author":"Schally","year":"1971","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clinthera.2006.10.018_bib19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1210\/endo-90-6-1561","article-title":"Stimulation of the FSH and LH release in vitro by natural and synthetic LH and FSH releasing hormone","volume":"90","author":"Schally","year":"1972","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/endo-91-2-529","article-title":"Stimulation of FSH release in vivo by prolonged infusion of synthetic LH-RH","volume":"91","author":"Arimura","year":"1972","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib21","series-title":"Central Nervous System Effects of Hypothalamic Hormones and Other Peptides","first-page":"317","article-title":"Structure-function studies and prediction of conformational requirements for LH-RH","author":"Coy","year":"1979"},{"key":"10.1016\/j.clinthera.2006.10.018_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jcem-37-4-626","article-title":"The half-life, metabolism and excretion of titrated luteinizing hormone-releasing hormone (LH-RH) in man","volume":"37","author":"Redding","year":"1973","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.10.018_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/j.1879-3479.1980.tb00507.x","article-title":"LHRH agonists and antagonists","volume":"18","author":"Schally","year":"1980","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.clinthera.2006.10.018_bib24","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1021\/ja00897a025","article-title":"Solid phase peptide synthesis. I. The synthesis of a tetrapeptide","volume":"85","author":"Merrifield","year":"1963","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.clinthera.2006.10.018_bib25","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/1841648b0","article-title":"Assay of plasma insulin in human subjects by immunological methods","volume":"184","author":"Yalow","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2006.10.018_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.181.4095.177","article-title":"Induction of mating behavior in rats by luteinizing hormone-releasing factor","volume":"181","author":"Moss","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2006.10.018_bib27","first-page":"208","article-title":"Effect of hypothalamic extracts on release of growth hormone in vitro","volume":"119","author":"Schally","year":"1965"},{"key":"10.1016\/j.clinthera.2006.10.018_bib28","series-title":"Recent Progress on GnRH and Gonadal Peptides","first-page":"15","article-title":"Gonadotropin-releasing hormone (GnRH) generalities","author":"Schaison","year":"1990"},{"key":"10.1016\/j.clinthera.2006.10.018_bib29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1210\/endo-84-6-1517","article-title":"Elevation of plasma LH concentrations induced by LH-releasing factor as measured by radioimmunoassay in the sheep","volume":"84","author":"Amoss","year":"1969","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1210\/endo-93-5-1092","article-title":"Production of antiserum to LHreleasing hormone (LH-RH) associ ated with gonadal atrophy in rabbits: Development of radioimmunoassays for LH-RH","volume":"93","author":"Arimura","year":"1973","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0006-291X(77)91579-0","article-title":"Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormonereleasing hormone agonist of human chorionic gonadotropin","volume":"76","author":"Auclair","year":"1977","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2006.10.018_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1126\/science.100883","article-title":"Hypophysial responses to continuous and intermittent delivery of hy popthalamic gonadotropin-releasing hormone","volume":"202","author":"Belchetz","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2006.10.018_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/j.1939-4640.1980.tb00034.x","article-title":"Antifertility effects of LHRH agonists in the male","volume":"1","author":"Labrie","year":"1980","journal-title":"J Androl."},{"key":"10.1016\/j.clinthera.2006.10.018_bib34","first-page":"6509","article-title":"Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone","volume":"78","author":"Redding","year":"1981"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.10.018_bib35","first-page":"295","article-title":"Anti-tumour potential of a new luteinizing hormone releasing hormone analogue, ICI 118630","author":"Nicholson","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0022-4731(80)90182-X","article-title":"Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6 des-GIyNH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men","volume":"13","author":"Belanger","year":"1980","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.clinthera.2006.10.018_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jcem-48-1-167","article-title":"Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6LH-RH-EA10","volume":"48","author":"Smith","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib38","first-page":"293","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2006.10.018_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"10.1016\/j.clinthera.2006.10.018_bib40","first-page":"267","article-title":"New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen","volume":"5","author":"Labrie","year":"1982","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.clinthera.2006.10.018_bib41","first-page":"1658","article-title":"Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists","volume":"79","author":"Tolis","year":"1982"},{"key":"10.1016\/j.clinthera.2006.10.018_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/bmj.289.6443.468","article-title":"Failure of long term luteinising hormone releasing hormone treat ment for prostate cancer to suppress serum luteinising hormone and testosterone","volume":"289","author":"Kerle","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.clinthera.2006.10.018_bib43","author":"Southern Research Institute"},{"key":"10.1016\/j.clinthera.2006.10.018_bib44","first-page":"19","article-title":"Studies of a controlled-release microcapsule formulation of an LH RH agonist (D Trp-6-LH-RH) in the rhesus monkey menstrual cycle","volume":"30","author":"Asch","year":"1985","journal-title":"Int J Fertil"},{"key":"10.1016\/j.clinthera.2006.10.018_bib45","first-page":"5845","article-title":"Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D Trp6]luteinizing hormonereleasing hormone from injectable microcapsules","volume":"81","author":"Redding","year":"1984"},{"key":"10.1016\/j.clinthera.2006.10.018_bib46","first-page":"417","article-title":"Disparate effects of daily versus continuous administration of a po tent LH-RH agonist on plasma LH levels in female rhesus monkeys","volume":"39","author":"Vickery","year":"1983","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clinthera.2006.10.018_bib47","first-page":"143","article-title":"Biodegradable sustained release formulation of the LH-RH analogue \u2018Zoladex\u2019 for the treatment of hormone-responsive tumors","volume":"185A","author":"Furr","year":"1985","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.clinthera.2006.10.018_bib48","series-title":"Decapeptyl\u00ae. Trelstar\u00ae\/Decapeptyl\u00ae","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.018_bib49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1464-410X.1973.tb12238.x","article-title":"Plasma testosterone: An accurate monitor of hor mone treatment in prostatic cancer","volume":"45","author":"Shearer","year":"1973","journal-title":"Br J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib50","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1097\/00000421-198801102-00038","article-title":"How would you like to have an orchidectomy for advanced prostatic cancer?","volume":"11","author":"Parmar","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: Impli cations for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib52","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0196-9781(99)00130-8","article-title":"Luteinizing hormonereleasing hormone analogs: Their impact on the control of tumorigenesis","volume":"20","author":"Schally","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.clinthera.2006.10.018_bib53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.290.6463.185","article-title":"Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer","volume":"290","author":"Ahmed","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.clinthera.2006.10.018_bib54","series-title":"Presented at: Seventh International Congress of Endocrinology","article-title":"Treatment of prostatic tumors by the LH-RH agonist D-Tryp6-LH-RH: Efficacy of a long-acting form upon testosterone, LH and D-Tryp6-LHRH plasma levels","author":"Roger","year":"1984"},{"key":"10.1016\/j.clinthera.2006.10.018_bib55","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/joe.0.103R001","article-title":"Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)","volume":"103","author":"Walker","year":"1984","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0140-6736(85)90739-1","article-title":"Randomised controlled study of orchidectomy vs long-acting D Trp-6-LHRH microcapsules in advanced prostatic carcinoma","volume":"2","author":"Parmar","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.10.018_bib57","series-title":"Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment","first-page":"307","article-title":"Randomized multicenter trial: Triptorelin vs surgical castra tion, long term results and prognostic factors","author":"Botto","year":"1994"},{"key":"10.1016\/j.clinthera.2006.10.018_bib58","first-page":"581","article-title":"Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy","volume":"56","author":"De Sy","year":"1988","journal-title":"Acta Urol Belg"},{"key":"10.1016\/j.clinthera.2006.10.018_bib59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2006.10.018_bib60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","article-title":"Systematic review and meta analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib61","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.10.018_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/sj.pcan.4500265","article-title":"Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A metaanalysis of nine published randomized controlled trials and 4128 patients using flutamide","volume":"2","author":"Bennett","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clinthera.2006.10.018_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clinthera.2005.02.016","article-title":"The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: Considerations for optimal use","volume":"27","author":"Teillac","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.10.018_bib64","author":"American Cancer Society"},{"key":"10.1016\/j.clinthera.2006.10.018_bib65","first-page":"71","article-title":"Medical therapy of prostate cancer. A review","volume":"57","author":"Roscigno","year":"2005","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib66","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0022-5347(01)66670-9","article-title":"Estrogens in the treatment of prostate cancer","volume":"154","author":"Cox","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib67","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2004.04.579","article-title":"American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer","volume":"22","author":"Loblaw","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib68","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410x.2000.00528.x","article-title":"Differential response of prostate specific antigen to testosterone surge after luteinizing hormonereleasing hormone analogue in prostate cancer and benign prostatic hyperplasia","volume":"85","author":"Agarwal","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.10.018_bib69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/er.2004-0017","article-title":"Gonadotropin-releasing hormone agonists in the treatment of prostate cancer","volume":"26","author":"Labrie","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2006.10.018_bib70","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/jnci\/93.22.1687","article-title":"Androgen receptor signaling in androgen-refractory prostate cancer","volume":"93","author":"Grossmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2006.10.018_bib71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11912-005-0077-y","article-title":"Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies","volume":"7","author":"Armstrong","year":"2005","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2006.10.018_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.mou.0000165548.87039.ff","article-title":"Update in the management of patients with hormone-refractory prostate cancer","volume":"15","author":"Moore","year":"2005","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib73","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mito xantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.10.018_bib74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-5347(01)67270-7","article-title":"Practice trends in the diagnosis and management of prostate cancer in the United States","volume":"154","author":"Gee","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eursup.2005.04.003","article-title":"Role of luteinising hormone releasing hormone (LHRH) agonists and hormonal treatment in the management of prostate cancer","volume":"4","author":"Mongiat-Artus","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2006.10.018_bib76","series-title":"Campbell's Urology","first-page":"3055","article-title":"Diagnosis and staging of prostate cancer","author":"Carter","year":"2002"},{"key":"10.1016\/j.clinthera.2006.10.018_bib77","series-title":"UrologicPathology: The Prostate","first-page":"171","article-title":"The Veterans Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostatic carcinoma","author":"Gleason","year":"1977"},{"key":"10.1016\/j.clinthera.2006.10.018_bib78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0090-4295(02)01639-4","article-title":"Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?","volume":"60","author":"Labrie","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1464-410X.2005.05390.x","article-title":"An evidence-based approach to understanding the phar macological class effect in the management of prostatic diseases","volume":"95","author":"Evans","year":"2005","journal-title":"BJU W"},{"issue":"Suppl 3A","key":"10.1016\/j.clinthera.2006.10.018_bib80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(97)00170-2","article-title":"Neoadjuvant hormonal therapy: The Canadian experience","volume":"49","author":"Labrie","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib81","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0022-5347(05)67008-5","article-title":"Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated?","volume":"164","author":"Scolieri","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00005392-200101000-00030","article-title":"Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy","volume":"165","author":"Blute","year":"2001","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.10.018_bib83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urology.2003.08.004","article-title":"Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer","volume":"62","author":"Pisansky","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0360-3016(96)00513-5","article-title":"Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer","volume":"37","author":"Laverdiere","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clinthera.2006.10.018_bib85","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III Radiation Therapy Oncology Group (RTOG) trial 86 10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clinthera.2006.10.018_bib86","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clinthera.2006.10.018_bib87","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.10.018_bib89","first-page":"19","article-title":"Radical perineal prostatectomy subsequent to bilateral orchiectomy","volume":"16","author":"Vallett","year":"1944","journal-title":"Delaware Med J"},{"key":"10.1016\/j.clinthera.2006.10.018_bib90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0090-4295(94)80241-6","article-title":"Down-staging of early stage prostate cancer before radical prostatecto my: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist","volume":"44","author":"Labrie","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib91","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000473789","article-title":"The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment","volume":"29","author":"Hugosson","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib92","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-5347(01)67067-8","article-title":"Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer","volume":"154","author":"Soloway","year":"1995","journal-title":"J Urol"},{"issue":"Suppl 3A","key":"10.1016\/j.clinthera.2006.10.018_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0090-4295(97)00171-4","article-title":"Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma","volume":"49","author":"Witjes","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1464-410X.2002.02982.x","article-title":"Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial","volume":"90","author":"Aus","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.10.018_bib95","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib96","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year followup results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3NOMO prostate cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.10.018_bib97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000052544","article-title":"Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out","volume":"39","author":"Van Poppel","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","article-title":"Risk of prostate carcinoma death in patients with lymph node metastasis","volume":"91","author":"Cheng","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib99","first-page":"396","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: Results at 10 years of EST 3886","volume":"169","author":"Messing","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council Trial","volume":"79","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib101","first-page":"392","article-title":"Comparison of early versus late hormonal therapy (HT) following early PSA-only recurrence (ePSAR) within the Department of Defense CenterforProstate Disease Research database","volume":"22","author":"Reynolds","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.018_bib102","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eursup.2005.01.002","article-title":"Hormone therapy in prostate cancer-moving into the 21st century","volume":"4","author":"Whelan","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2006.10.018_bib103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1464-410X.2006.06176.x","article-title":"Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer","volume":"98","author":"Mottet","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.10.018_bib105","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/01.ju.0000091640.59812.83","article-title":"The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer","volume":"170","author":"Cherrier","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib106","first-page":"191","article-title":"Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations","volume":"4","author":"Bruchovsky","year":"2000","journal-title":"Mol Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib107","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","article-title":"Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression","volume":"64","author":"Higano","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib108","first-page":"1809","article-title":"Intermittent androgen suppression in prostate cancer: An update of the Vancouver experience","volume":"10","author":"Pether","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib111","author":"European Organisation for Research and Treatment of Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.10.018_bib112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(02)02393-2","article-title":"Hormonal therapy: Historical perspective to future directions","volume":"61","author":"Mcleod","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib113","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropinreleasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib114","first-page":"71","article-title":"Bone loss in prostate cancer: Evaluation, treatment and prevention","volume":"12","author":"Saad","year":"2005","journal-title":"Can J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib116","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation thera py for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib117","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib118","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment- related osteoporosis in men with prostate carcinoma","volume":"97","author":"Smith","year":"2003","journal-title":"Cancer"},{"issue":"Suppl 12","key":"10.1016\/j.clinthera.2006.10.018_bib119","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2006.10.018_bib120","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib121","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.10.018_bib122","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2006.10.018_bib123","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib124","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ncpuro0326","article-title":"Therapy insight: Osteoporosis during hormone therapyfor prostate cancer","volume":"2","author":"Smith","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib125","series-title":"In a Phase III lipid interim analysis, Acapodene treatment lowered cholesterol and raised HDL in prostate cancer patients on androgen deprivation therapy","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.018_bib126","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004","volume":"20","author":"Bekker","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2006.10.018_bib127","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685530500361226","article-title":"The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer","volume":"8","author":"Boxer","year":"2005","journal-title":"Aging Male"},{"key":"10.1016\/j.clinthera.2006.10.018_bib128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1464-410X.2005.05565.x","article-title":"Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study","volume":"96","author":"Jenkins","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.10.018_bib130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1464-410X.2003.04010.x","article-title":"Health-related quality of life in men with metastatic prostate cancer: The misleading effect of lead-time bias","volume":"91","author":"Litwin","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.10.018_bib131","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-5347(05)67947-5","article-title":"High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers","volume":"163","author":"Halmos","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.10.018_bib132","first-page":"7269","article-title":"Cytotoxic analogs of luteinizing hormone-releasing hormone con taining doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500\u20131000 times more potent","volume":"93","author":"Nagy","year":"1996"},{"key":"10.1016\/j.clinthera.2006.10.018_bib133","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0024-3205(03)00113-9","article-title":"New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin","volume":"72","author":"Schally","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2006.10.018_bib134","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tem.2004.07.002","article-title":"Chemotherapy targeted to cancers through tumoral hormone receptors","volume":"15","author":"Schally","year":"2004","journal-title":"Trend Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.10.018_bib135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.20335","article-title":"Inhibition of human experimental prostate cancers by a tar geted cytotoxic luteinizing hormonereleasing hormone analog AN-207","volume":"66","author":"Stangelberger","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.clinthera.2006.10.018_bib136","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/en.2004-1353","article-title":"Effects of KiSST peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat","volume":"146","author":"Navarro","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib137","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1210\/en.2005-0323","article-title":"Differential regulation of KiSS-1 mRNA expression by sex steroids in the brain of the male mouse","volume":"146","author":"Smith","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.10.018_bib138","first-page":"75","article-title":"Gene therapy","volume":"51","author":"Gotoh","year":"2005","journal-title":"Ninyokika Kiyo"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180600258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180600258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:46Z","timestamp":1758962866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180600258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":136,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S014929180600258X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}